RINGSIDE part A
95 evidence topics · 9 sources
Objective
Study purpose: safety, preliminary efficacy, and selection of the phase III dose regimen
Post hoc analysis objective: treatment response in key subgroups
Exploratory analysis objective: T2-weighted signal intensity, tumor volume, and exposure-response
Location and study date
Screening and enrollment from October 2021 to July 2022 at 21 academic medical centers in seven countries
Transition to the open-label extension from October 2022 to May 2023 and data as of January 6, 2025
Study start and data cutoff
Enrollment completed as of March 2022 and interim data as of January 3, 2023
Registry dates and study identifier
| Field | Quoted record |
|---|---|
| First posted | “2021-05-04” |
| Study start (actual) | “2021-09-01” |
| Other study ID | “AL-DES-01” |
Study design
Open-label, randomized, dose-finding phase II part of a phase II/III trial
Registry design: Part A dose regimen finding and Part B placebo-controlled study
Dose selection after the last week 16 MRI and entry into the open-label extension
MRI schedule in the phase 2 part and the open-label extension
Transition to the open-label extension between week 36 and week 76
Eligibility criteria
Inclusion criteria: adults with histologically confirmed, progressing desmoid tumors
Registry inclusion criteria for Part A
Registry exclusion criteria for Parts A and B: cardiac, laboratory, and prior treatment
Open-label extension inclusion and exclusion criteria
Treatment
Randomization 1:1:1 to 1.2 mg once daily, 2 mg intermittent, or 4 mg intermittent
Treatment duration and switch to 1.2 mg once daily in the open-label extension
Registry arms of Part A and the open-label extension
Dose regimens: 2 mg and 4 mg on two days each week or 1.2 mg daily
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Primary endpoint: safety based on treatment-emergent adverse events
Registry primary outcome: frequency and severity of TEAEs and SAEs
Rationale: dose selection on safety and tolerability in a dose-finding study
Adverse events of special interest: ovarian toxicity, liver enzyme elevations, and nonmelanoma skin cancers
Secondary endpoint: change in tumor volume from baseline to week 16 by BICR
Rationale for volumetric MRI assessment
Exploratory endpoints: RECIST v1.1 objective response rate, duration of response, and MRI signal biomarkers
Rationale for T2-weighted signal intensity as a marker of tumor cellularity
Primary, secondary, and exploratory endpoints
Open-label extension endpoints in the registry
Statistical analysis description
Number of participants (Planned and analyzed)
Sample size: 12 participants per dose regimen for 85% power
Participants enrolled, MRI-evaluable, and entering the open-label extension
Registry enrollment
| Field | Quoted record |
|---|---|
| Enrollment (actual) | “198” |
Evaluable population of 36 participants
Interim evaluable populations by dose regimen
Description of analysis sets
Analysis of covariance of tumor volume change and confidence intervals for response
Evaluable population: at least one post-baseline scan
Subgroup analysis set: subgroups with at least 5 participants, pooled across dose regimens
Post hoc imaging analysis methods
Results
Participant disposition
Screening, enrollment, and discontinuation during the randomized trial
Exposure by dose arm during the randomized trial
Open-label extension: 29 participants and 12 remaining on treatment as of January 6, 2025
Time on treatment as of April 10, 2024: median 25.4 months
Time on treatment as of April 10, 2024: median 23.1 months
Baseline characteristics
Age, sex, mutation status, and prior therapy
Demographic and clinical characteristics by dose arm
| Characteristic | 1.2 mg once daily (n = 14) | 2 mg intermittent (n = 14) | 4 mg intermittent (n = 14) | All doses (N = 42) |
|---|---|---|---|---|
| Age, years, mean (SD) | “42.1 (11.32)” | “37.8 (14.76)” | “39.9 (13.99)” | “39.9 (13.23)” |
| Female, No. (%) | “11 (78.6)” | “9 (64.3)” | “11 (78.6)” | “31 (73.8)” |
| Women of childbearing potential, No. (%) | “9 (64.3)” | “7 (50.0)” | “7 (50.0)” | “23 (54.8)” |
| Intra-abdominal tumor at screening, No. (%) | “3 (21.4)” | “4 (28.6)” | “3 (21.4)” | “10 (23.8)” |
| Tumor volume at baseline by BICR, cm3, mean (SD) | “83.93 (92.280)” | “189.17 (368.846)” | “166.91 (211.038)” | “146.05 (242.664)” |
| CTNNB1 mutation, No. (%) | “8 (57.1)” | “4 (28.6)” | “8 (57.1)” | “20 (47.6)” |
| APC mutation, No. (%) | “2 (14.3)” | “5 (35.7)” | “2 (14.3)” | “9 (21.4)” |
| Prior systemic therapy, No. (%) | “9 (64.3)” | “13 (92.9)” | “7 (50.0)” | “29 (69.0)” |
| Prior surgery, No. (%) | “7 (50.0)” | “8 (57.1)” | “4 (28.6)” | “19 (45.2)” |
| Prior radiation therapy, No. (%) | “1 (7.1)” | “2 (14.3)” | “1 (7.1)” | “4 (9.5)” |
| Unidimensional tumor growth by ≥10% within 18 months of screening, No. (%) | “11 (78.6)” | “14 (100.0)” | “10 (71.4)” | “35 (83.3)” |
| Tumor-related pain not adequately controlled with nonopioid medicine, No. (%) | “5 (35.7)” | “5 (35.7)” | “5 (35.7)” | “15 (35.7)” |
Median age, performance status, and median baseline tumor volume
| Characteristic | 1.2 mg once daily (n=14) | All doses (N=42) |
|---|---|---|
| Age (years), median (min, max) | “44.0 (24, 61)” | “38.5 (19, 72)” |
| ECOG performance status 0, n (%) | “14 (100.0)” | “35 (83.3)” |
| ECOG performance status 1, n (%) | “0” | “7 (16.7)” |
| Intra-abdominal tumor at initial diagnosis, n (%) | “5 (35.7)” | “12 (28.6)” |
| Extra-abdominal tumor at initial diagnosis, n (%) | “9 (64.3)” | “30 (71.4)” |
| Tumor volume at baseline (cm3), median (min, max) | “46.30 (1.4, 244.9)” | “65.10 (1.4, 1270.3)” |
Efficacy results
Median best percent change by dose arm during the randomized trial
Tumor response by BICR per RECIST v1.1 during the randomized trial
| Response | 1.2 mg once daily (n = 14) | 2 mg intermittent (n = 14) | 4 mg intermittent (n = 14) | All doses (N = 42) |
|---|---|---|---|---|
| Partial response, No. (%) | “5 (35.7)” | “3 (21.4)” | “3 (21.4)” | “11 (26.2)” |
| Stable disease, No. (%) | “7 (50.0)” | “6 (42.9)” | “10 (71.4)” | “23 (54.8)” |
| Progressive disease, No. (%) | “0” | “2 (14.3)” | “0” | “2 (4.8)” |
| Not available, No. (%) | “2 (14.3)” | “3 (21.4)” | “1 (7.1)” | “6 (14.3)” |
| Objective response 95% CI | “12.8 to 64.9” | “4.7 to 50.8” | “4.7 to 50.8” | “13.9 to 42.0” |
| Time to objective response, weeks, median (min, max) | “30.00 (17.3, 40.9)” | “40.29 (38.3, 41.0)” | “51.00 (40.3, 53.7)” | “40.29 (17.3, 53.7)” |
Selection of 1.2 mg once daily for phase III
Pharmacokinetic exposure by dose regimen
Open-label extension: tumor volume, sum of diameters, and T2-weighted signal by original dose arm
Tumor response by BICR per RECIST v1.1 in the randomized trial and open-label extension combined
| Response | Original 1.2 mg once daily (n = 14) | Original 2 mg intermittent (n = 14) | Original 4 mg intermittent (n = 14) | All (N = 42) |
|---|---|---|---|---|
| Complete response, No. (%) | “0” | “1 (7.1)” | “1 (7.1)” | “2 (4.8)” |
| Partial response, No. (%) | “8 (57.1)” | “6 (42.9)” | “8 (57.1)” | “22 (52.4)” |
| Objective response, No. (%) | “8 (57.1)” | “7 (50.0)” | “9 (64.3)” | “24 (57.1)” |
| Objective response 95% CI | “28.9 to 82.3” | “23.0 to 77.0” | “35.1 to 87.2” | “41.0 to 72.3” |
| Time to objective response, weeks, median (min, max) | “37.71 (17.3, 65.1)” | “40.57 (28.1, 101.6)” | “63.00 (40.3, 121.3)” | “51.50 (17.3, 121.3)” |
| Duration of response, weeks, median (95% CI) | “NE (46.1 to NE)” | “NE (24.9 to NE)” | “NE (NE to NE)” | “NE (NE to NE)” |
Exploratory imaging analysis: correlations and week 16 changes
Exposure-response modeling: predicted median time to 30% tumor volume decrease of 3 months with 1.2 mg once daily
Objective response rate from 43% to 78% across subgroups
| Subgroup | Responders, No. (%) |
|---|---|
| Age ≤40 years (n=22) vs. >40 years (n=14) | “13 (59) vs. 10 (71)” |
| Tumor size <70 mm (n=18) vs. ≥70 mm (n=14) | “13 (72) vs. 9 (64)” |
| Prior lines of therapy: 0 (n=11), 1 (n=16), or 2+ (n=9) | “6 (55), 10 (63), 7 (78)” |
| Intra-abdominal (n=9) vs. extra-abdominal (n=27) | “4 (44) vs. 19 (70)” |
| APC (n=7) vs CTNNB1 (n=19) mutation | “3 (43) vs. 13 (68)” |
Objective response and duration of response by subgroup as of January 6, 2025
“Data cutoff: Jan. 6, 2025” (opens the source at this quote in a new tab)
“ORR by RECIST ranged from 50% to 78%” (opens the source at this quote in a new tab)
“Median DOR ranged from 37.1 to 79.8 weeks” (opens the source at this quote in a new tab)
“Responses were seen in all subgroups examined” (opens the source at this quote in a new tab)
| Subgroup | ORR, n (%) | DOR, weeks, median (min, max) |
|---|---|---|
| All MRI-evaluable patients (n=37) | “24 (65)” | “58.9 (12.1, 120.6)” |
| Age ≤40 years (n=22) | “13 (59)” | “66.1 (22.1, 110.0)” |
| Age >40 years (n=15) | “11 (73)” | “37.1 (12.1, 120.6)” |
| Tumor size <70 mm (n=19) | “10 (53)” | “52.1 (22.1, 99.0)” |
| Tumor size ≥70 mm (n=18) | “14 (78)” | “78.4 (12.1, 120.6)” |
| Prior lines of therapy 0 (n=11) | “6 (55)” | “79.8 (22.1, 95.9)” |
| Prior lines of therapy 1 (n=13) | “9 (69)” | “37.1 (12.1, 120.6)” |
| Prior lines of therapy 2+ (n=13) | “9 (69)” | “56.0 (12.1, 110.0)” |
| Intra-abdominal (n=10) | “5 (50)” | “46.1 (12.1, 99.0)” |
| Extra-abdominal (n=27) | “19 (70)” | “61.9 (12.1, 120.6)” |
| APC mutation (n=8) | “4 (50)” | “55.4 (12.1, 66.1)” |
| CTNNB1 mutation (n=19) | “13 (68)” | “79.6 (22.1, 120.6)” |
| CTNNB1 S45F (n=3) | “2 (67)” | “31.0 (24.9, 37.1)” |
| CTNNB1 T41A (n=5) | “2 (40)” | “88.2 (55.9, 120.6)” |
| CTNNB1 other (n=11) | “9 (82)” | “82.0 (22.1, 110.0)” |
Objective response and median best change in tumor volume in the evaluable population
| Response | 1.2 mg QD dose (n=12) | All doses (n=36) |
|---|---|---|
| Objective response rate (CR + PR), n (%) | “9 (75%)” | “23 (64%)” |
| Complete response, n (%) | “0 (0%)” | “2 (6%)” |
| Partial response, n (%) | “9 (75%)” | “21 (58%)” |
| Stable disease, n (%) | “3 (25%)” | “12 (33%)” |
| Progressive disease, n (%) | “0 (0%)” | “1 (3%)” |
| Disease control rate, n (%) | “12 (100%)” | “35 (97%)” |
Objective response in the evaluable and intention-to-treat populations
Interim partial response and tumor volume change at Week 16 and Week 28
Interim partial response and tumor volume change at Week 16 and Week 28, rounded values
Health-related quality of life and patient-reported outcomes
Patient-reported outcomes not analyzed because of limited data and small samples
Registered open-label extension GODDESS outcome measures
Safety results
Treatment-related adverse events: no grade 4 or 5 events and no treatment-related serious adverse events
Adverse events during the randomized trial: grade 3, serious, and most common events
Discontinuation because of adverse events by dose arm
Treatment-emergent adverse events during the randomized trial by dose arm
Adverse events of special interest: liver enzyme elevations, cutaneous squamous cell carcinoma, and ovarian toxicity
Adverse events of special interest by dose arm, appendix table
| Event, No. (%) | 1.2 mg once daily (n = 14) | 2 mg intermittent (n = 14) | 4 mg intermittent (n = 14) | All doses (N = 42) |
|---|---|---|---|---|
| One or more adverse events of special interest | “6 (42.9)” | “5 (35.7)” | “5 (35.7)” | “16 (38.1)” |
| Amenorrhea | “3 (21.4)” | “3 (21.4)” | “4 (28.6)” | “10 (23.8)” |
| Premature menopause | “0” | “0” | “1 (7.1)” | “1 (2.4)” |
| Elevated liver enzymes (CTCAE grade ≥2) | “2 (14.3)” | “2 (14.3)” | “0” | “4 (9.5)” |
| Squamous cell carcinoma of skin | “1 (7.1)” | “0” | “0” | “1 (2.4)” |
Open-label extension: five additional participants with treatment-related grade 3 adverse events
Treatment-emergent adverse events in the randomized trial and open-label extension combined
| Treatment-emergent adverse event, No. (%) | Original 1.2 mg once daily (n = 14) | Original 2 mg intermittent (n = 14) | Original 4 mg intermittent (n = 14) | All doses (N = 42) |
|---|---|---|---|---|
| Grade ≥3 | “6 (42.9)” | “11 (78.6)” | “6 (42.9)” | “23 (54.8)” |
| Treatment-related grade ≥3 | “4 (28.6)” | “6 (42.9)” | “4 (28.6)” | “14 (33.3)” |
| Serious | “1 (7.1)” | “6 (42.9)” | “1 (7.1)” | “8 (19.0)” |
| Leading to dose reduction | “7 (50.0)” | “3 (21.4)” | “8 (57.1)” | “18 (42.9)” |
| Leading to interruption | “11 (78.6)” | “8 (57.1)” | “9 (64.3)” | “28 (66.7)” |
| Leading to study drug withdrawal | “4 (28.6)” | “4 (28.6)” | “1 (7.1)” | “9 (21.4)” |
| Diarrhea | “14 (100.0)” | “9 (64.3)” | “12 (85.7)” | “35 (83.3)” |
| Nausea | “8 (57.1)” | “5 (35.7)” | “10 (71.4)” | “23 (54.8)” |
| Fatigue | “8 (57.1)” | “6 (42.9)” | “8 (57.1)” | “22 (52.4)” |
| Hypophosphatemia | “7 (50.0)” | “5 (35.7)” | “3 (21.4)” | “15 (35.7)” |
| Stomatitis | “7 (50.0)” | “5 (35.7)” | “3 (21.4)” | “15 (35.7)” |
| Cough | “3 (21.4)” | “5 (35.7)” | “6 (42.9)” | “14 (33.3)” |
| Rash | “1 (7.1)” | “7 (50.0)” | “6 (42.9)” | “14 (33.3)” |
| Upper respiratory tract infection | “3 (21.4)” | “2 (14.3)” | “6 (42.9)” | “11 (26.2)” |
Safety summary and grade 3 or higher adverse events as of January 6, 2025
“Data cutoff: Jan. 6, 2025” (opens the source at this quote in a new tab)
“8 pts (19%) had a serious adverse event (AE)” (opens the source at this quote in a new tab)
“9 pts (21%) discontinued due to an AE” (opens the source at this quote in a new tab)
“14 (33%) pts had treatment-related Grade 3 AEs” (opens the source at this quote in a new tab)
“No Grade 4-5 AEs” (opens the source at this quote in a new tab)
| Adverse event, n (%) | All grades (N=42) | Grade ≥3 (N=42) |
|---|---|---|
| Diarrhoea | “35 (83.3)” | “5 (11.9)” |
| Nausea | “23 (54.8)” | “0” |
| Fatigue | “22 (52.4)” | “2 (4.8)” |
| Hypophosphatemia | “15 (35.7)” | “0” |
| Stomatitis | “15 (35.7)” | “1 (2.4)” |
| Cough | “14 (33.3)” | “1 (2.4)” |
| Headache | “14 (33.3)” | “0” |
| Rash | “14 (33.3)” | “0” |
Updated safety: grade 3 drug-related TEAEs in 14 of 42 participants
Interim safety: grade 3 drug-related TEAEs in 26.2% of patients
Interim safety: grade 3 drug-related TEAE in 10 of 42 patients
Study limitations
Summary
- RINGSIDE Part A was an open-label, randomized, dose-finding phase II study with 14 participants in each of three varegacestat dose regimens and no placebo or active comparator arm; the investigators describe it as having “small sample sizes and no placebo or active comparator arm”. The primary endpoint was safety; change in tumor volume at week 16 by BICR was the secondary endpoint, and RECIST v1.1 objective response rate was exploratory.
- The sample size was powered for the change in tumor volume from baseline within each regimen (12 participants per regimen, 85% power), so comparisons between regimens are descriptive: the LS mean reduction at week 16 was statistically significant for 1.2 mg once daily (–39.8%) and not for the 2 mg (–21.7%) or 4 mg (–17.8%) intermittent regimens. The efficacy analysis set (37 MRI-evaluable participants, 88.1%) excluded participants without measurable disease at baseline or a valid MRI at week 4 or later.
- The open-label extension switched all 29 continuing participants (69.0%) to 1.2 mg once daily between week 36 and week 76, so long-term results by original dose arm (confirmed ORR 57.1%, 50.0%, and 64.3%) reflect both the randomized regimen and later exposure to 1.2 mg once daily. Participants could continue varegacestat after progression by BICR with sponsor approval.
- Response rates differ by data cutoff and analysis population: an evaluable-population ORR of 75% for 1.2 mg once daily and 64% for all doses (April 10, 2024), an intention-to-treat ORR of 55% for all doses in the 10-K, and a confirmed ORR of 57.1% among all 42 participants as of January 6, 2025. Two abstracts with the April 10, 2024 cutoff report different median times on treatment (25.4 and 23.1 months), and two interim abstracts report grade 3 drug-related TEAEs in 26.2% (January 3, 2023 cutoff) and in 10 of 42 participants (24%).
- Subgroup analyses were post hoc, pooled across dose regimens, and limited to subgroups with at least 5 participants; the investigators state that “The sample sizes in each subgroup are relatively small”. The T2-weighted signal and exposure-response analyses were exploratory.
- Patient-reported outcomes were not analyzed because of “limited data availability and small sample sizes”. Ovarian toxicity had not resolved at last follow-up in 6 of 12 affected women. The study was sponsored by Immunome and Ayala Pharmaceuticals.